Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix Reports Full Year Fiscal 2022 Results

October 31, 2022
RNS Number : 5791E Renalytix PLC 31 October 2022   Renalytix plc (" Renalytix ", the "Group" or the " Company ")   Renalytix Reports Full Year Fiscal 2022 Results   LONDON and SALT LAKE CITY , October 31, 2022   -  Renalytix plc   (NASDAQ: RNLX),  (LSE : RENX)   an artificial intelligence-enabled

Second Price Monitoring Extn

October 26, 2022
RNS Number : 1692E Renalytix PLC 26 October 2022   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

Price Monitoring Extension

October 26, 2022
RNS Number : 1684E Renalytix PLC 26 October 2022   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

KidneyIntelX Medicare Update

October 25, 2022
RNS Number : 9479D Renalytix PLC 25 October 2022     Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX   Medicare Update   NEW YORK and SALT LAKE CITY , October 25, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that, building on recently established private payer and

Notice of Results

October 24, 2022
RNS Number : 7880D Renalytix PLC 24 October 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31   NEW YORK and SALT LAKE CITY , October 24, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today

Presentations accepted at ASN Kidney Week

October 17, 2022
RNS Number : 0165D Renalytix PLC 17 October 2022     KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology   Four presentations, including first clinical utility findings from multi-year real world evidence results from a major

Directorate Change

September 20, 2022
RNS Number : 9534Z Renalytix PLC 20 September 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix Announces Change to Board of Directors   LONDON and SALT LAKE CITY , 20 September 2022 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that Ann Berman , non-executive director

Issue of shares

September 12, 2022
RNS Number : 0215Z Renalytix PLC 12 September 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 12 September, 2022 -   Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"),

Renalytix to Present at H.C. Wainwright Conference

September 8, 2022
RNS Number : 6200Y Renalytix PLC 08 September 2022     Renalytix   to Present at H.C. Wainwright 24th Annual Global Investment Conference   NEW YORK, NY and SALT LAKE CITY, UT    ̶  September 8, 2022   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a

Business update

August 17, 2022
RNS Number : 3072W Renalytix PLC 17 August 2022     This contains inside information Renalytix plc ("Renalytix" or the "Company")   Business update   NEW YORK, NY and SALT LAKE CITY, UT   August 17, 2022 (GLOBE NEWSWIRE)   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business
Displaying 171 - 180 of 385